Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teprotumumab - Horizon Therapeutics

Drug Profile

Teprotumumab - Horizon Therapeutics

Alternative Names: HZN 001; Insulin-like-growth-factor-1-receptor-antagonist-antibody-River-Vision-Development; R 1507; RG 1507; RO-4858696; RV 001-River-Vision; Tepezza; teprotumumab-trbw

Latest Information Update: 01 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Roche
  • Developer Horizon Therapeutics plc; Roche
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graves ophthalmopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Graves ophthalmopathy
  • Phase I Diffuse scleroderma
  • No development reported Diabetic macular oedema
  • Discontinued Advanced breast cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 30 Mar 2021 US FDA approves prior approval supplement (PAS) for teprotumumab in Graves ophthalmopathy
  • 30 Mar 2021 Horizon Therapeutics plans a clinical trial (Late-stage disease) for Graves ophthalmopathy in the mid-year 2021 (NCT04583735)
  • 30 Mar 2021 Horizon Therapeutics plans an exploratory clinical trial for Diffuse scleroderma in the mid-year 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top